Argenta Discovery Inc. and Zafgen Announce Contract Drug Discovery Collaboration in Obesity

Published: Jan 29, 2009

HARLOW, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Argenta Discovery Ltd., the contract research and Respiratory R & D company, and Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced that they have entered into a major drug discovery collaboration. Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism and pharmacokinetics to accelerate development candidate nomination for one of Zafgen’s innovative therapeutics programs for obesity.

Back to news